N/A
Completed N=52
Non-Inferiority Study of the FRESCA Airbox Positive Airway Pressure System
Source: ClinicalTrials.gov NCT03999944 ↗Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Apnea-Hypopnea Index (AHI) — 3.20; 4.86 events/hr
Summary
Prospective, open-label, randomized crossover assignment, multi-center non-inferiority study conducted in the United States
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Apnea-Hypopnea Index (AHI) |
3.20; 4.86 | — |
| SECONDARY Oxygen Desaturation Index (ODI) |
3.12; 4.69 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female aged 22 - 75 years old.
- BMI: ≤ 40 kg/m2.
- Subjects diagnosed with OSA (either newly diagnosed (naive) OSA subjects or current CPAP subjects).
- Must be able to be fitted properly with FRESCA mask.
- Must be able to comply with all study requirements as outlined in the protocol.
- Subject must complete a valid PSG titration night.
Exclusion Criteria
- Subjects with non-OSA sleep disorders (including periodic limb movement (PLM) disorder and chronic insomnia).
- Subjects with substantial central or mixed apneas (central and mixed apnea ≥ 5/hr.).
- Subjects with prior surgical intervention for OSA.
- Subjects with frequent or sustained episodes of O2 saturation ≤75%.
- Subjects with obesity-related hypoventilation.
- Subjects currently using a CPAP full face mask.
- Subjects who are medically unstable.
- Subjects with unstable or severe cardiovascular abnormalities (e.g., heart failure, valvular heart disease).
- Subjects with atrial fibrillation or other arrhythmias that are not effectively controlled with medication.
- Subjects with hypotension or uncontrolled HTN.
- Subjects with chronic lung disease, including COPD.
- Subjects with significant cardiopulmonary disease.
- Subjects with ongoing severe nasal allergies or sinusitis or difficulty breathing through the nose; persistent blockage of one or both nostrils; or any nasal or facial abnormalities that would not allow adequate placement and use of the mask.
- Subjects with surgery of the upper airway, nose, sinus or middle ear within the previous year.
- Subjects currently working nights, rotating night shifts or with planned travel during the study period.
- Subjects on a non-stable dose of medications or other agents that may affect sleep and/or PSG (e.g., sedatives or hypnotics).
- Subjects who consume > 500 mg caffeine per day (e.g., > 8 cola-type beverages, > 5 cups of coffee).
- Subjects who consume > 14 alcoholic drinks/week.
- Subjects who are pregnant (confirmed verbally).
- Subjects currently enrolled in any other research study.
Data sourced from ClinicalTrials.gov (NCT03999944). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.